AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22835900 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PD fluids (neutral-pH, low glucose degradation product 1.5% glucose solution; 1.1% amino acid solution; 7.5% icodextrin)
Number of subjects: 150
Study 22835900 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD fluid
Number of subjects: 150
Study 20644121 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA-2000 treatment including anthracycline-based consolidation and all-trans retinoic acid (ATRA) for 15 days during each consolidation.
Number of subjects: 636
Study 20644121 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA-2000 treatment for high-risk patients including anthracycline-based consolidation and ATRA.
Number of subjects: 636
Study 20644121 — intervention group
Group type: COMPARATOR
Intervention: AIDA-0493 treatment including cytarabine-containing regimens for high-risk patients.
Number of subjects: 636
Study 20644121 — intervention group
Group type: COMPARATOR
Intervention: AIDA-0493 treatment including cytarabine-containing regimens for low/intermediate-risk patients.
Number of subjects: 636
Study 18753119 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interviewing (ACASI)
Number of subjects: 180
Study 18753119 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-administered questionnaire (IAQ)
Number of subjects: 180
Study 15878048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologically based family therapy (EBFT)
Number of subjects: 124
Study 15878048 — intervention group
Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 124
Study 12553397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 30
Study 12553397 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% garlic
Number of subjects: 30
Study 12553397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% tea tree oil
Number of subjects: 30
Study 12553397 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 30
Study 9607056 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-valent pneumococcal conjugate vaccine (PCV); three doses separated by two months; types 6B, 14, 18C, 19F, and 23F
Number of subjects: 41
Study 9607056 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo; three doses
Number of subjects: 41
Study 7634946 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenum-preserving resection of the head of the pancreas (DPRHP)
Number of subjects: 43
Study 7634946 — intervention group
Group type: COMPARATOR
Intervention: Whipple procedure (PD)
Number of subjects: 43
Study 2096747 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose atracurium/lidocaine combination
Number of subjects: 40
Study 2096747 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 40
Study 509932 — intervention group
Group type: EXPERIMENTAL
Intervention: Baracaide
Number of subjects: 0
Study 509932 — intervention group
Group type: COMPARATOR
Intervention: Swarfega
Number of subjects: 0
Study 509932 — intervention group
Group type: COMPARATOR
Intervention: Go‐Jo
Number of subjects: 0
Study 31426362 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3‐PUFA alone (800 mg DHA and 225 mg EPA daily)
Number of subjects: 1680
Study 31426362 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus placebo
Number of subjects: 1680
Study 31426362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ω3‐PUFA and multidomain intervention
Number of subjects: 1680
Study 31426362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1680
Study 30246185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fo3 (fixed-on-3) implants
Number of subjects: 48
Study 30246185 — intervention group
Group type: COMPARATOR
Intervention: Fo4 (fixed-on-4) implants
Number of subjects: 48
Study 28445193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% R348
Number of subjects: 30
Study 28445193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% R348
Number of subjects: 30
Study 28445193 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 30
Study 28445193 — intervention group
Group type: COMPARATOR
Intervention: 0.5% R348, 0.2% R348, Vehicle
Number of subjects: 30
Study 25636332 — intervention group
Group type: EXPERIMENTAL
Intervention: Study intervention arm
Number of subjects: 14
Study 25636332 — intervention group
Group type: COMPARATOR
Intervention: Contact-time comparison intervention arm
Number of subjects: 14
Study 23895820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (VitD3) supplementation, 2,000 IU oral daily for 6 weeks
Number of subjects: 101
Study 23895820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 23895820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (VitD3) supplementation
Number of subjects: 101
Study 20799388 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 671
Study 20799388 — intervention group
Group type: COMPARATOR
Intervention: Conventional Glucose Monitoring (Standard Care Group)
Number of subjects: 671
Study 19075203 — intervention group
Group type: COMPARATOR
Intervention: Surgery (primarily decompressive laminectomy for stenosis)
Number of subjects: 634
Study 19075203 — intervention group
Group type: COMPARATOR
Intervention: Surgery (decompressive laminectomy with fusion for degenerative spondylolisthesis)
Number of subjects: 634
Study 19075203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative care
Number of subjects: 634
Study 16779534 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment
Number of subjects: 0
Study 16779534 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 0
Study 16779534 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14684758 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian ginseng (0, 1, 2, and 3 g)
Number of subjects: 22
Study 14684758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g)
Number of subjects: 22
Study 10871810 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromotor rehabilitative treatment
Number of subjects: 0
Study 10871810 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 0
Study 10871810 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilometric platform 'BIOGP'
Number of subjects: 0
Study 9180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise for 12 weeks
Number of subjects: 66
Study 9180065 — intervention group
Group type: COMPARATOR
Intervention: Flexibility exercises and relaxation therapy for 12 weeks
Number of subjects: 66
Study 9180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise after crossover from flexibility treatment
Number of subjects: 66
Study 9180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise treatment
Number of subjects: 66
Study 8466022 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (1 g/250 mL normal saline)
Number of subjects: 36
Study 8466022 — intervention group
Group type: COMPARATOR
Intervention: Saline (250 mL normal saline)
Number of subjects: 36
Study 3889875 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 60
Study 3889875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal intake of dietary fiber
Number of subjects: 157
Study 30959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal intake of saturated fatty acids (SFA)
Number of subjects: 157
Study 30959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal intake of mono-unsaturated fatty acids (MUFA)
Number of subjects: 157
Study 30959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal intake of poly-unsaturated fatty acids (PUFA)
Number of subjects: 157
Study 30959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal protein intake
Number of subjects: 157
Study 30959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 157
Study 30959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient inadequacy for vitamin D
Number of subjects: 157
Study 30959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient inadequacy for thiamine
Number of subjects: 157
Study 28340145 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181 (100 mg, 200 mg, 400 mg)
Number of subjects: 42
Study 28340145 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181 (400 mg)
Number of subjects: 42
Study 28340145 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (40 mg)
Number of subjects: 42
Study 28340145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28340145 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181
Number of subjects: 42
Study 26678983 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week informed consent information training
Number of subjects: 50
Study 26678983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 50
Study 26135957 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of SCREAM Theater intervention
Number of subjects: 1390
Study 26135957 — intervention group
Group type: COMPARATOR
Intervention: One dose of SCREAM Theater intervention
Number of subjects: 1390
Study 22773673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-screw implant
Number of subjects: 30
Study 22773673 — intervention group
Group type: COMPARATOR
Intervention: Transpalatal arch
Number of subjects: 30
Study 20237760 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg remifentanil
Number of subjects: 60
Study 20237760 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg remifentanil
Number of subjects: 60
Study 20237760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18554236 — intervention group
Group type: EXPERIMENTAL
Intervention: GI-Mentor II simulator training (5 hours) plus bedside training
Number of subjects: 20
Study 18554236 — intervention group
Group type: COMPARATOR
Intervention: Non-simulator group (bedside training only)
Number of subjects: 20
Study 16515105 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine, 1 ml (30 mg) of ketorolac and 9 ml of saline intra-articularly (Group C)
Number of subjects: 90
Study 16515105 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of intra-articular saline and 10 ml of 0.25% bupivacaine (Group B)
Number of subjects: 90
Study 16515105 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of intra-articular saline (Group A)
Number of subjects: 90
Study 14527527 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with sertraline and cognitive-behavior therapy (CBT)
Number of subjects: 10
Study 14527527 — intervention group
Group type: COMPARATOR
Intervention: Sertraline alone
Number of subjects: 10
Study 10515020 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment (n = 15)
Number of subjects: 31
Study 10515020 — intervention group
Group type: COMPARATOR
Intervention: Sham control (n = 16)
Number of subjects: 31
Study 8720019 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message
Number of subjects: 3826
Study 8720019 — intervention group
Group type: COMPARATOR
Intervention: Handwritten envelopes and machine-printed labels
Number of subjects: 3826
Study 8720019 — intervention group
Group type: COMPARATOR
Intervention: Formal invitation, business letter with inside name and address, business letter without recipient's name and address
Number of subjects: 3826
Study 3046626 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (M) 200 mg SR qd
Number of subjects: 143
Study 3046626 — intervention group
Group type: COMPARATOR
Intervention: low-Na/high-K salt (S) 2 g bid
Number of subjects: 143
Study 30654882 — intervention group
Group type: COMPARATOR
Intervention: Combination of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily
Number of subjects: 1448
Study 30654882 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 5 mg twice daily alone
Number of subjects: 1448
Study 28882385 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating mesh (VM) with 5000 μg salbutamol
Number of subjects: 36
Study 28882385 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizers (JN) with 5000 μg salbutamol
Number of subjects: 36
Study 28882385 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with AeroChamber Vent (MDI-AV) with 1600 μg salbutamol
Number of subjects: 36
Study 25804100 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded slow breathing training
Number of subjects: 20
Study 25804100 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded slow breathing training
Number of subjects: 20
Study 25804100 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 20
Study 24273930 — intervention group
Group type: EXPERIMENTAL
Intervention: Urtica dioica leaf extract (500 mg capsule every 8 hours for 3 months)
Number of subjects: 46
Study 24273930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 20467757 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.25 mg i.v. bolus 30 min before TMZ)
Number of subjects: 33
Study 18456877 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA) assessments
Number of subjects: 0
Study 18456877 — intervention group
Group type: COMPARATOR
Intervention: Paper assessments
Number of subjects: 0
Study 21874971 — intervention group
Group type: EXPERIMENTAL
Intervention: In-situ simulation training
Number of subjects: 3
Study 21874971 — intervention group
Group type: COMPARATOR
Intervention: TeamSTEPPS didactic training program
Number of subjects: 3
Study 21874971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3
Study 16220085 — intervention group
Group type: EXPERIMENTAL
Intervention: NFV + RTV + ddI
Number of subjects: 41
Study 16220085 — intervention group
Group type: COMPARATOR
Intervention: NFV + NVP + d4T
Number of subjects: 41
Study 12239424 — intervention group
Group type: EXPERIMENTAL
Intervention: Seresis (antioxidative combination containing carotenoids, vitamins C and E, selenium, and proanthocyanidins)
Number of subjects: 0
Study 12239424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12239424 — intervention group
Group type: EXPERIMENTAL
Intervention: Seresis
Number of subjects: 0
Study 9570193 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 231
Study 9570193 — intervention group
Group type: EXPERIMENTAL
Intervention: NASCET-eligible patients
Number of subjects: 231
Study 7923235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma-vinyl GABA) treatment, initial dose of 10 mg/kg per day progressively increased up to a maximum of 140 mg/kg per day, in addition to conventional concomitant therapy.
Number of subjects: 69
Study 7923235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin treatment
Number of subjects: 69
Study 3292753 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative diflunisal
Number of subjects: 50
Study 3292753 — intervention group
Group type: COMPARATOR
Intervention: Preoperative placebo
Number of subjects: 50
Study 12410546 — intervention group
Group type: EXPERIMENTAL
Intervention: valepotriates (mean daily dose: 81.3 mg)
Number of subjects: 36
Study 12410546 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (mean daily dose: 6.5 mg)
Number of subjects: 36
Study 12410546 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 30205353 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1241
Study 30205353 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatization
Number of subjects: 1241
Study 30205353 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 1241
Study 30205353 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptoms
Number of subjects: 1241
Study 25863790 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief parenting discussion group (n=45)
Number of subjects: 85
Study 25863790 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=40)
Number of subjects: 85
Study 25863790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=45)
Number of subjects: 85
Study 25106708 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIF with porous ceramic corundum implants
Number of subjects: 100
Study 25106708 — intervention group
Group type: COMPARATOR
Intervention: Decompression by fenestration
Number of subjects: 100
Study 25106708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PLIF and decompression)
Number of subjects: 100
Study 22131290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal temperature controlled laminar airflow (TLA)
Number of subjects: 312
Study 22131290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 20171235 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participants performing the vigilance tasks (difficult and easy versions)
Number of subjects: 0
Study 20171235 — intervention group
Group type: EXPERIMENTAL
Intervention: Easier vigilance task
Number of subjects: 0
Study 20171235 — intervention group
Group type: EXPERIMENTAL
Intervention: More difficult vigilance task
Number of subjects: 0
Study 20171235 — intervention group
Group type: COMPARATOR
Intervention: No-work control group
Number of subjects: 0
Study 18534052 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-purite 0.1% BID
Number of subjects: 207
Study 18534052 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine-purite 0.15% BID
Number of subjects: 207
Study 16243338 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical bipolar vessel sealing (EBVS)
Number of subjects: 68
Study 16243338 — intervention group
Group type: COMPARATOR
Intervention: Traditional suturing
Number of subjects: 68
Study 11856620 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 90
Study 11856620 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated influenza vaccine (LIV)
Number of subjects: 90
Study 11856620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LIV and IIV (LIV/IIV)
Number of subjects: 90
Study 11856620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10375359 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO treatment
Number of subjects: 26
Study 10375359 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 26
Study 7556806 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 100
Study 7556806 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 100
Study 2190537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cepharanthin (CEP) 60 mg/day p.o.
Number of subjects: 106
Study 2190537 — intervention group
Group type: COMPARATOR
Intervention: Control (no CEP administration)
Number of subjects: 106
Study 2190537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cepharanthin (CEP)
Number of subjects: 106
Study 340643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular nalbuphine (3 and 6 mg or 6 and 12 mg)
Number of subjects: 56
Study 340643 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (4 mg and 8 mg)
Number of subjects: 56
Study 340643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular nalbuphine
Number of subjects: 56
Study 340643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine and nalbuphine
Number of subjects: 56
Study 31163012 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy of adjuvant radiotherapy delivered in 1.5-Gy fractions twice per day over 2 weeks along with 15 mg/m2 docetaxel once per week (Cohort A)
Number of subjects: 80
Study 31163012 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy of adjuvant radiotherapy with a simultaneous integrated boost to nodal levels with extranodal extension to 36 Gy in 1.8-Gy fractions twice per day (Cohort B)
Number of subjects: 80
Study 31163012 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive RT de-escalation
Number of subjects: 80
Study 28524036 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-district triage standard
Number of subjects: 1106
Study 28524036 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-level triage standard
Number of subjects: 1106
Study 28524036 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-district and four-level triage standards
Number of subjects: 1106
Study 25757757 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 73
Study 25757757 — intervention group
Group type: COMPARATOR
Intervention: Nontreated patients
Number of subjects: 73
Study 25757757 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy and hematoma volume
Number of subjects: 73
Study 23602498 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 40
Study 23602498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20689451 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (1200 mg)
Number of subjects: 20
Study 20689451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 min of one-legged kicking at 55% of workload maximum)
Number of subjects: 20
Study 20689451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19921356 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm catheter length
Number of subjects: 120
Study 19921356 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 cm catheter length
Number of subjects: 120
Study 16923248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins E and C supplementation
Number of subjects: 22
Study 16923248 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 22
Study 14615303 — intervention group
Group type: EXPERIMENTAL
Intervention: First-order motion processing in V1
Number of subjects: 0
Study 14615303 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-order motion processing in later occipital visual areas
Number of subjects: 0
Study 14615303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical specialization for first- and second-order motion
Number of subjects: 0